• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

    11/12/24 5:00:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email

    HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2024, along with key recent updates.

    Recent Highlights

    • Partnership and Presentations with Enable Injections: Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina's lead candidate, SER-252 (POZ-apomorphine), with Enable's enFuse™ wearable drug delivery platform. This innovative partnership aims to enhance patient comfort and convenience, providing continuous dopaminergic stimulation (CDS) for Advanced Parkinson's Disease patients through easy-to-administer subcutaneous injections.

    Third Quarter Operating Results

    Revenues: Revenues comprised entirely of grant revenues from the National Institutes of Health in the amount of $14 thousand and $29 thousand for three months ended September 30, 2024 and 2023, respectively.

    Operating expenses: Operating expenses for the three months ended September 30, 2024 and 2023 were $5.3 million and $1.5 million, respectively.

    Research and development expenses for the three months ended September 30, 2024, increased by $1.8 million to $2.4 million as compared to $0.6 million for the same period in 2023. The net increase was primarily due to $0.8 million in salaries and payroll related expenses due to increase in headcount, $0.5 million in professional fees for the maintenance of certain patent and other intellectual property and biological material assets included in Legacy Assets, and $0.5 million in outside research services and consultants for research programs.

    General and administrative expenses for the three months ended September 30, 2024, increased $2.0 million to $2.9 million as compared to $0.9 million for the same period in 2023. The increase is attributable to increases of (1) $0.9 million of stock based compensation expenses as a result of new directors and new hire option grants, (2) $0.5 million of consulting expenses to assist with the implementation of new platforms and software, (3) a non-recurring $0.3 million severance expenses (4) $0.2 million in compensation and related expenses as a result of increased headcount (5) $0.2 million in directors and officers insurance, and (6) $0.2 million in miscellaneous expenses that were individually insignificant. These expenses were offset by a decrease of $0.3 million in professional legal and accounting services incurred largely in connection with the Merger which consummated on March 26, 2024.

    Other income, net for the three months ended September 30, 2024 increased $3.5 million to $6.7 million as compared to $3.2 million for the same period in 2023. The increase was primarily attributable to an increase of $6.1 million in the gain from the change in fair value of liability classified Merger Warrants offset by the loss in the fair value of the Legacy Serina Convertible Notes and the AgeX-Serina Note of $2.6 million.

    Net income: The net income attributable to Serina for the three months ended September 30, 2024 was $1.4 million, or $0.16 per share (basic) and $0.13 per share (diluted) compared to net income of $1.8 million, or $0.80 per share (basic) and $0.23 per share (diluted), for 2023.

    Liquidity Information

    Cash, cash equivalents, and restricted cash totaled $3.2 million as of September 30, 2024.

    Going Concern Considerations

    As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), the Company evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on the Company's most recent projected cash flows, the Company believes that its cash and cash equivalents of $3.2 million as of September 30, 2024 with the approximately $10 million of cash proceeds expected to be received from Juvenescence through the exercise of Juvenescence's remaining Post-Merger Warrants as provided in a "Side Letter" would not be sufficient to satisfy the Company's anticipated operating and other funding requirements for the twelve months following the filing of the Company's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2024. These factors raise substantial doubt regarding the ability of the Company to continue as a going concern.

    About SER-252 (POZ-apomorphine)

    SER 252 is an investigational apomorphine therapy developed with Serina's POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson's disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.

    About the POZ Platform™

    Serina's proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina's POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina's product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

    Serina's POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina's POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.

    About Serina Therapeutics

    Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.

    For more information, please visit https://serinatherapeutics.com.

    Cautionary Statement Regarding Forward-Looking Statement

    This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2023, the company's Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company's other periodic reports and documents filed from time to time with the SEC.

    The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

    For inquiries, please contact:

    [email protected]

    (256) 327-9630

    SERINA THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except par value amounts)

      September 30, 2024  December 31, 2023 
       (unaudited)      
    ASSETS        
    Current assets:        
    Cash and cash equivalents $3,185  $7,619 
    Grant receivable  14   — 
    Prepaid expenses and other current assets  2,224   — 
    Total current assets  5,423   7,619 
             
    Restricted cash  50   — 
    Property and equipment, net  519   573 
    Right of use assets - operating leases  509   666 
    Right of use assets - finance leases  92   110 
    Intangible assets, net  509   — 
    Other long-term prepaid assets  333   — 
    TOTAL ASSETS $7,435  $8,968 
             
    LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' DEFICIT        
    Current liabilities:        
    Accounts payable $1,695  $580 
    Accrued expenses  1,159   583 
    Loans due to Juvenescence, net of debt issuance costs  10,462   — 
    Other current liabilities  198   250 
    Total current liabilities  13,514   1,413 
             
    Warrant liability  6,744   — 
    Loans due to Juvenescence, net of current portion  693   — 
    Convertible promissory notes, at fair value  —   2,983 
    Operating lease liabilities, net of current portion  312   461 
    Finance lease liabilities, net of current portion  —   1 
    TOTAL LIABILITIES  21,263   4,858 
             
    Commitments and contingencies (Note 11)        
    Redeemable convertible preferred stock:        
    Redeemable convertible preferred stock, $0.01 par value; 10,000 authorized; none and 3,438 issued and outstanding at September 30, 2024 and December 31, 2023, respectively; Liquidation preference of none and $36,981,810 at September 30, 2024 and December 31, 2023, respectively  —   36,404 
    Stockholders' deficit:        
    Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding  —   — 
    Common stock, $0.0001 par value, 40,000 shares authorized; and 8,892 and 2,410 shares issued and outstanding  1   25 
    Additional paid-in capital  8,000   858 
    Accumulated deficit  (21,775)  (33,177)
    Total Serina Therapeutics, Inc. stockholders' deficit  (13,774)  (32,294)
    Noncontrolling interest  (54)  — 
    Total stockholders' deficit  (13,828)  (32,294)
    TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' DEFICIT $7,435  $8,968 



    See accompanying notes to these condensed consolidated interim financial statements.

    SERINA THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

      Three Months Ended

    September 30,
      Nine Months Ended

    September 30,
     
      2024  2023  2024  2023 
    REVENUES            
    Grant revenues $14  $29  $70  $66 
    Total revenues  14   29   70   66 
                     
    OPERATING EXPENSES                
    Research and development  2,415   603   5,115   1,481 
    General and administrative  2,911   889   6,454   1,955 
    Total operating expenses  5,326   1,492   11,569   3,436 
                     
    Loss from operations  (5,312)  (1,463)  (11,499)  (3,370)
                     
    OTHER INCOME (EXPENSE), NET                
    Interest expense  (16)  (100)  (509)  (382)
    Fair value inception adjustment on convertible promissory note  —   —   —   2,240 
    Change in fair value of convertible promissory notes  —   2,614   (7,017)  4,477 
    Change in fair value of warrants  6,669   596   10,385   1,059 
    Other income, net  42   105   185   194 
    Total other income, net  6,695   3,215   3,044   7,588 
                     
    NET INCOME (LOSS)  1,383   1,752   (8,455)  4,218 
    Net loss attributable to noncontrolling interest  27   —   54   — 
                     
    NET INCOME (LOSS) ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. $1,410  $1,752  $(8,401) $4,218 
                     
    NET EARNINGS (LOSS) PER COMMON SHARE:                
    BASIC $0.16  $0.80  $(1.24) $1.94 
    DILUTED $0.13  $0.23  $(1.24) $0.57 
                     
    WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:                
    BASIC  8,851   2,190   6,774   2,176 
    DILUTED  10,751   7,584   6,774   7,548 

    See accompanying notes to these condensed consolidated interim financial statements.

    SERINA THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

    (unaudited)

      Nine Months Ended

    September 30,
     
      2024  2023 
    OPERATING ACTIVITIES:        
    Net income (loss) $(8,455) $4,218 
    Adjustments to reconcile net income (loss) to net cash used in operating activities:        
    Depreciation and amortization  138   84 
    Non-cash lease expense  174   139 
    Non-cash interest expense on convertible promissory note  163   382 
    Amortization of debt issuance costs  337   — 
    Stock-based compensation  1,607   25 
    Fair value inception adjustment on convertible promissory note  —   (2,240)
    Change in fair value of convertible promissory notes  7,017   (4,477)
    Change in fair value of warrants  (10,385)  (1,059)
    Changes in operating assets and liabilities:        
    Grant receivable  51   — 
    Prepaid expenses and other current assets  (2,449)  2 
    Accounts payable  (712)  523 
    Accrued expenses  132   (62)
    Operating lease liabilities  (166)  (132)
    Net cash used in operating activities  (12,548)  (2,597)
             
    INVESTING ACTIVITIES:        
    Purchase of equipment  (17)  (434)
    Net cash used in investing activities  (17)  (434)
             
    FINANCING ACTIVITIES:        
    Drawdown on loan facilities from Juvenescence  2,933   — 
    Cash and restricted cash acquired in connection with the Merger  337   — 
    Proceeds from the exercise of stock options  90   15 
    Proceeds from the exercise of Post-Merger Warrants by Juvenescence  4,988   — 
    Proceeds from the issuance of convertible promissory notes  —   10,100 
    Principal repayment on loan facilities to Juvenescence  (133)  — 
    Principal repayments on finance lease liabilities  (34)  (35)
    Net cash provided by financing activities  8,181   10,080 
             
    NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH $(4,384) $7,049 
             
    CASH, CASH EQUIVALENTS AND RESTRICTED CASH:        
    At beginning of the period $7,619  $532 
    At end of the period $3,235  $7,581 
             
    SUPPLEMENTAL DISCLOSURES        
    Cash paid for interest $2  $4 
    SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES:        
    Right of use asset acquired in exchange for operating lease liabilities $—  $672 
    Issuance of common stock upon conversion of Preferred Stock $36,404  $— 
    Issuance of common stock upon conversion of AgeX-Serina Note $10,721  $— 
    Merger and issuance of common stock upon consummation of Merger on March 26, 2024 $961  $— 

    See accompanying notes to these condensed consolidated interim financial statements.



    Primary Logo

    Get the next $SER alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    7/14/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $SER
    SEC Filings

    View All

    SEC Form 144 filed by Serina Therapeutics Inc.

    144 - Serina Therapeutics, Inc. (0001708599) (Subject)

    10/14/25 4:48:41 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    10/6/25 4:12:48 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Serina Therapeutics Inc.

    DEFA14A - Serina Therapeutics, Inc. (0001708599) (Filer)

    9/26/25 12:19:07 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Moreadith Randall exercised 4,326 shares at a strike of $0.06 and sold $22,495 worth of shares (4,326 units at $5.20) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    10/14/25 1:16:19 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 47,674 shares at a strike of $0.06 and sold $331,418 worth of shares (47,674 units at $6.95) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    8/27/25 5:16:39 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Moreadith Randall exercised 4,304 shares at a strike of $0.06 and sold $22,284 worth of shares (4,304 units at $5.18) (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    8/20/25 5:13:25 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

    HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch of a comprehensive corporate communications platform designed to deliver timely, transparent updates to patients, clinicians, investors, and the broader scientific community. The new initiative expands Serina's direct channels of communication to provide stakeholders with clear, accessible information on the Company's programs, regulatory progress, and scientific advances. The platform will feature regular digital updates, educational resources, multimedia

    10/8/25 11:00:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

    $5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the drawdown of the first $5 million tranche from its previously announced financing agreement, which provides up to $20 million in funding upon achievement of defined development milestones. Proceeds will be used to advance the Company's planned registrational trial of SER-252 for the treatment of adva

    10/6/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

    Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson's under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that it has entered into an agreement to access up to $20 million in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised,

    9/9/25 3:20:56 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/24/24 4:30:06 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/20/24 6:59:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Serina Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $15.00

    7/14/25 8:54:25 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    View All

    Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

    - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

    5/22/25 4:50:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

    HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

    2/12/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

    HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors. "We are excited to welcome Karen to the Board of Directors. Karen's financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients," said Steve Ledger, Serina's Chief Executive Officer. Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently se

    1/14/25 5:25:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    12/9/24 4:45:59 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    7/5/24 4:01:13 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Financials

    Live finance-specific insights

    View All

    Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. "We're proud of the momentum we've built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurologic

    8/11/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

    HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the "Annual Meeting"). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina's 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pur

    7/1/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

    On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation

    5/8/25 4:23:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care